GMED Globus Medical Inc Class A

Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting

Globus Medical to feature ExcelsiusFlex™ for Total Knee Arthroplasty at the American Academy of Orthopedic Surgeons Annual Meeting

AUDUBON, Pa., March 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced it will participate in the 2025 Annual Meeting of the American Academy of Orthopedic Surgeons (AAOS) in San Diego, Calif., from March 10-14, 2025.

Join Globus at booth #2517 to learn about the comprehensive Globus Medical product portfolio across Spine, Trauma, and Joint Reconstruction procedures; Enabling Technology; Power Tools; and Regenerative Biomaterials segments.

Globus will be featuring one of its latest technology innovations, the ExcelsiusFlex™ surgical robotic navigation system for Total Knee Arthroplasty (TKA), alongside its Total Joints Arthroplasty implant portfolio*. Engineered to outperform, ExcelsiusFlex™ with TKA Application consolidates accuracy, procedural flexibility, and surgeon-centric design while allowing customization of workflow for surgeon preferences, imaging modalities, and patient needs.

Globus will also feature the PRECICE™ Intramedullary Limb Lengthening Portfolio, our Power Tools Portfolio including the DuraPro™ Oscillating System, and the Harvest™ SmartPrep™ 3 autologous biologic centrifuge platform.

Globus welcomes AAOS attendees to attend a reception to meet members of the Globus Medical team and learn more about our technology offerings.

Wednesday, March 12, 2025 – 5:30pm – 8:30pm

Globus Medical Reception

San Diego Wine & Culinary Center

200 Harbor Drive, San Diego, CA

  

Globus Medical will also be hosting a booth tour for analysts and investors to see our latest innovative technologies and solutions in person at the conference.

Wednesday, March 12, 2025 – 1:00pm – 1:45pm

Globus Medical Investor Relations Booth Tour

AAOS Conference Floor, Booth #2517

"AAOS provides us with the unique opportunity to showcase our comprehensive portfolio of musculoskeletal procedures and enabling technology," said John Mulcahy, Chief Commercial Officer at Globus Medical. "We look forward to connecting with our surgeon partners and showcasing our latest procedural innovations including the next generation in robotics for TKA applications."

Learn more about our events at AAOS:

Learn more about our Globus Medical Product Portfolio:

*ExcelsiusFlex is indicated for use with the GENflex2™ and ACTIFY™ Total Knee Systems.

About Globus Medical, Inc.

Based in Audubon, Pennsylvania, Globus Medical, Inc. is a leading global musculoskeletal company dedicated to solving unmet clinical needs and changing lives. We innovate with inspired urgency, provide world-class education and clinical support, and advance care throughout spine, orthopedic trauma, joint reconstruction, regenerative biomaterials and enabling technologies. Additional information can be accessed at .

Safe Harbor Statements 

All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, the risks and costs associated with the integration of, and the ability of Globus Medical and NuVasive to integrate, their businesses successfully and to achieve anticipated synergies, health epidemics, pandemics and similar outbreaks, including the COVID-19 pandemic, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with laws and regulations that are or may become applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at . Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Investor contact:

Brian Kearns

610-930-1800

Media contact:

Moran Chavez



EN
06/03/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Globus Medical Inc Class A

 PRESS RELEASE

Globus Medical Announces Leadership Transitions and Preliminary Second...

Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results AUDUBON, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer, has been appointed President and Chief Executive Officer effective July 18, 2025. Daniel Scavilla has resigned as President and Chief Executive Officer effective July 18, 2025, in order to pursue another opportunity. Additionally, Kyle Kline, Senior Vice ...

 PRESS RELEASE

Globus Medical Schedules Second Quarter Earnings Release and Conferenc...

Globus Medical Schedules Second Quarter Earnings Release and Conference Call AUDUBON, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- , Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2025 after the market close on Thursday, August 7, 2025. A copy of the release will be available on the Globus Medical website at . Following the announcement, Globus Medical will hold a teleconference to discuss its performance with the investment community at 4:30 p.m. Eastern Time. Participants may access the conference call...

 PRESS RELEASE

Globus Medical Introduces DuraPro™ with Navigation, a Next-Generation,...

Globus Medical Introduces DuraPro™ with Navigation, a Next-Generation, Oscillating System Designed to Safeguard Delicate Tissue AUDUBON, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its next-generation oscillating system, DuraPro™, as the latest addition to the Power Portfolio, designed to advance procedural workflows through safety features and efficiency. “Our goal is to revolutionize the $550 million high-speed drill market with the introduction ...

 PRESS RELEASE

Globus Medical Announces $500 Million Share Repurchase Program

Globus Medical Announces $500 Million Share Repurchase Program AUDUBON, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of the Company’s outstanding common stock. “We believe the recent volatility in our share price has created a meaningful disconnect between our intrinsic value and our market valuation,” said Keith Pfeil, Chief Financial Officer and Chief Operating Officer of Globus Medical. “Given our strong tr...

 PRESS RELEASE

Globus Medical Reports First Quarter 2025 Results

Globus Medical Reports First Quarter 2025 Results AUDUBON, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025. Worldwide net sales were $598.1 million, a decrease of 1.4%, or a decrease of 0.8% on a constant currency basisGAAP net income for the quarter was $75.5 millionGAAP diluted earnings per share (“EPS”) was $0.54 and non-GAAP diluted EPS was $0.68 “Our first quarter results were impacted by softer Enabling Technology deal closures, tempo...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch